NCLT orders JB Pharma-Torrent merger vote in 2026

The Ahmedabad Bench of the National Company Law Tribunal (NCLT) has directed J.B. Chemicals & Pharmaceuticals Ltd. and Torrent Pharmaceuticals Ltd. to convene meetings of their equity shareholders for a proposed scheme of amalgamation under Sections 230 to 232 of the Companies Act, 2013. J.B. Chemicals is the transferor company and Torrent Pharmaceuticals is the transferee company under the scheme. The companies have stated that the merger is intended to enhance product offerings, expand customer coverage, and improve operational efficiencies. Both companies are headquartered in Ahmedabad and fall under the Registrar of Companies, Gujarat.

NCLT direction and what it covers

The tribunal’s direction relates to the first motion process for the amalgamation and requires the companies to seek equity shareholder approval through convened meetings. The NCLT also set key procedural conditions, including the use of video conferencing or other audio-visual means. The order required that the equity shareholder meetings be convened within 45 days of the order, and specified a quorum of 30 shareholders. The companies also informed the tribunal that no proceedings or investigations were pending against either company, as per the material shared.

A related update noted that the NCLT order was uploaded on the tribunal’s official website on March 23, 2026. A corrigendum order dated March 24, 2026 was uploaded on March 25, 2026.

Appointed date and structure of the amalgamation

Under the scheme, J.B. Chemicals is proposed to be merged into Torrent Pharmaceuticals, with an appointed date of January 21, 2026. In a separate scheme description, the appointed date is linked to the completion of Torrent’s acquisition of promoter shares in J.B. Chemicals. The amalgamation is structured so that J.B. Chemicals would be dissolved without winding up once the scheme becomes effective, and its shareholders (other than Torrent) would become shareholders of Torrent.

The companies have said the scheme is intended to serve the interests of shareholders, creditors, employees, and other stakeholders, and that it would not prejudice the rights of any shareholder, director, or creditor. The scheme also states that creditors of J.B. Chemicals will become creditors of Torrent, without any reduction in claims.

Shareholder meetings: dates, mode, and voting window

J.B. Chemicals published newspaper advertisements for the notice of its equity shareholders meeting in Indian Express (English, All India editions) and Sandesh (Gujarati, Gujarat edition) on March 28, 2026. The meeting is scheduled for April 28, 2026 at 2:00 p.m. IST and will be conducted through video conferencing or other audio-visual means. The cut-off date disclosed for this meeting is April 21, 2026.

Torrent Pharmaceuticals also issued a notice for a shareholder meeting convened by the NCLT to consider and approve the scheme on April 28, 2026, to be held via video conferencing or other audio-visual means. A separate meeting time disclosed for Torrent’s meeting is 10:00 a.m. IST.

Remote e-voting has been provided from April 24 to April 27, 2026, and e-voting at the meeting will be available for those who did not vote through the remote window.

Capital structure and shareholder base disclosed

The filings cited in the material include details of each company’s share capital and shareholder count. J.B. Chemicals reported an authorised share capital of ₹20.3 crore and paid-up capital of ₹16.05 crore, with over 69,000 equity shareholders. Torrent Pharmaceuticals reported an authorised share capital of ₹235 crore and paid-up capital of ₹169.22 crore, with over 76,000 equity shareholders.

The scheme text also states that the combined entity’s authorised share capital would increase to ₹255.3 crore, comprising 460.6 million equity shares of ₹5 each and 2.5 million preference shares of ₹100 each.

Exchange ratio, acquisition price, and valuation inputs

The scheme and supporting documents referenced valuation reports from Ernst & Young and BDO Valuation Advisory LLP, and fairness opinions from Axis Capital and ICICI Securities. The exchange ratio described is 51 equity shares of Torrent (face value ₹5 each) for every 100 equity shares of J.B. Chemicals (face value ₹1 each) held by shareholders other than Torrent.

Separately, the materials also refer to a binding agreement signed on June 29, 2025 at ₹1,600 per J.B. Chemicals share in connection with Torrent’s acquisition of J.B. Chemicals.

Creditors’ meetings and tribunal dispensations

The NCLT dispensed with the convening of meetings of secured creditors for both companies based on consent affidavits. J.B. Chemicals reported one secured creditor, while Torrent Pharmaceuticals reported eight secured creditors. The tribunal’s direction in this regard reduces one procedural step in the first motion process, based on the consents submitted.

Regulatory disclosures and complaint status

J.B. Chemicals stated it fulfilled disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The regulatory filing informing BSE about the publication of the newspaper advertisement was signed by the Company Secretary and Vice President - Secretarial, Sandeep Phadnis, on March 28, 2026.

The materials also refer to complaints reports submitted to BSE and NSE for the amalgamation process. The reports covering July 24, 2025 to December 17, 2025 showed zero complaints received directly or forwarded by the exchanges or SEBI.

Financial context and acquisition-related disclosures

A scheme summary included Torrent’s total revenue for the nine months ended December 31, 2025 at ₹9,783 crore, up from ₹8,557 crore in the same period last year. Another disclosure referenced exceptional items of ₹10 crore for a quarter, relating to costs associated with the J.B. Chemicals acquisition.

In J.B. Chemicals’ H1 FY26 consolidated results shared in the provided material, revenue from operations was ₹2,178.84 crore (converted from ₹2,17,884 lakh) and net profit after tax was ₹410.20 crore (converted from ₹41,020 lakh). The same update stated that the Competition Commission of India (CCI) approved the acquisition on October 21, 2025, subject to voluntary modifications.

Why the shareholder vote matters next

The tribunal-directed shareholder meetings are a required step for the amalgamation to proceed through the Companies Act route. The scheme remains subject to shareholder approval and further regulatory and tribunal processes as applicable. For investors, the immediate focus is on the voting timeline, the exchange ratio, and the procedural milestones already recorded, including the NCLT order and its corrigendum upload dates.

If the scheme is approved by shareholders in the convened meetings, the companies can proceed with subsequent steps required to complete the amalgamation under the applicable legal process.